An FDA ad­vi­so­ry com­mit­tee vot­ed Thurs­day to rec­om­mend ex­pand­ing ac­cess to a pop­u­lar pep­tide used by health and well­ness en­thu­si­asts for re­pair­ing mus­cles and heal­ing...

Sar­to­rius ap­pears to be the first life sci­ence com­pa­ny to de­tail how tar­iff re­funds are af­fect­ing its rev­enue, fol­low­ing the US Supreme Court de­ci­sion to...

The FDA said it will end a pi­lot that was in­tend­ed to help drug­mak­ers proac­tive­ly ad­dress pro­duc­tion is­sues. Few com­pa­nies took ad­van­tage of the pro­gram...

Mer­ck CEO Rob Davis said he has warned Con­gress and the Trump ad­min­is­tra­tion that if they cut off or ham­per US-Chi­na deal­mak­ing, the US could lose...

It’s no se­cret that sales of Leqem­bi have been dis­ap­point­ing.

First ap­proved in 2023, the Alzheimer’s drug from Ei­sai and Bio­gen launched short­ly af­ter Chris...

Re­ta­tru­tide, the obe­si­ty can­di­date that has shown the most pow­er­ful weight loss in late-stage tri­als, will be filed for ap­proval ear­ly next year, its de­vel­op­er...